Arzeda and KENT Specialty Milling Partner on AI Protein Design Collaboration
Arzeda and KENT Specialty Milling have entered a product development collaboration to create new proteins using AI-based design technology, announced in a press release.
The partnership will combine Arzeda's Intelligent Protein Design Technology with KENT's application and market expertise to explore new methods that improve performance and efficiency across target markets. The collaboration is intended to design and validate novel proteins with specific performance characteristics.
Arzeda's platform uses AI-based design, lab testing, and process development to create and manufacture proteins tailored for particular applications. KENT Specialty Milling contributes manufacturing and market knowledge to help move these innovations toward scalable production. Specific technical milestones have not been disclosed.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Arkestro adds recurring supplier price reviews and MCP connectivity
AstraZeneca and Oracle Partner on AI for Clinical Trials
Perplexity and Valarian Bring AI Tools Into Customer Infrastructure
NVIDIA Debuts RFD4-Proteina and Expands Radiotherapy Work
Daily AI Brief: the AI news that matters, in your inbox.